Outcomes with imetelstat in myelofibrosis: a systematic review and meta-analysis

Imetelstat has demonstrated potential benefit in reversing marrow fibrosis in MF. This meta-analysis aims to evaluate outcomes of Imetelstat in MF patients. A total of 197 MF patients were included from 3 studies. JAK2 mutation was reported in 62% of patients. 33% were refractory to JAKi. The pooled overall survival (OS) at 1 year was 80.95% (95% CI: 74.95-86.93, p = 0.54, I² = 0.0%). The pooled OS ranged from 19.9 to 33.8 months. The pooled SVR of 10%, 20% and 35% was 22.40 (95% CI 0.0-50.76, p = 0.0001), 11.44 (95% CI 0.00-30.95, p = 0.0006), and 4.42 (95% CI 0.0-14.31, p = 0.0152), respectively, while the pooled reduction of more than one grade in BM fibrosis was reported in 14.79% (95% CI: 4.70-24.88, p = 0.04, I²=67.5%). This meta-analysis demonstrates the efficacy of Imetelstat in MF patients who have relapsed on or are refractory to JAK inhibitors.